Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02374242

Recruitment Status : Active, not recruiting

First Posted : February 27, 2015

Last Update Posted : March 19, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Melanoma and Skin Cancer Trials Limited

Bristol-Myers Squibb

Information provided by (Responsible Party):

Melanoma Institute Australia

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	September 4, 2017
Estimated Study Completion Date :	December 2028

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.

To Top